# Vera Golder

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vera-golder/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,829 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 24 |
| i10-index | 36 |
| Last Known Institution | Novartis (Switzerland) |
| OpenAlex ID | https://openalex.org/A5050765170 |
| ORCID iD | 0000-0001-5691-4344 |
| Works | 111 |

## Researcher papers

- [Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study](https://scholariq.org/papers/lupus-low-disease-activity-state-as-a-treatment-endpoint-for-systemic-lupus/)
- [Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study](https://scholariq.org/papers/association-of-the-lupus-low-disease-activity-state-lldas-with-health-related/)
- [Ankylosing spondylitis: an update.](https://scholariq.org/papers/ankylosing-spondylitis-an-update/)
- [Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus](https://scholariq.org/papers/lupus-low-disease-activity-state-lldas-discriminates-responders-in-the-bliss-52/)
- [Discordance of patient and physician health status concerns in systemic lupus erythematosus](https://scholariq.org/papers/discordance-of-patient-and-physician-health-status-concerns-in-systemic-lupus/)
- [Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study](https://scholariq.org/papers/factors-associated-with-damage-accrual-in-patients-with-systemic-lupus-2/)
- [Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic](https://scholariq.org/papers/association-of-asian-ethnicity-with-disease-activity-in-sle-an-observational/)
- [Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study](https://scholariq.org/papers/lupus-low-disease-activity-state-and-remission-and-risk-of-mortality-in-patients/)
- [Treatment targets in SLE: remission and low disease activity state](https://scholariq.org/papers/treatment-targets-in-sle-remission-and-low-disease-activity-state/)
- [Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus](https://scholariq.org/papers/lupus-low-disease-activity-state-attainment-in-the-phase-3-tulip-trials-of/)
- [Treatment patterns, treat-to-target goals and clinical outcomes of patients with active lupus nephritis: real-world evidence from a multicentre cohort study](https://scholariq.org/papers/treatment-patterns-treat-to-target-goals-and-clinical-outcomes-of-patients-with/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Cytomegalovirus and herpesvirus research](https://scholariq.org/topics/cytomegalovirus-and-herpesvirus-research/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

## Researcher university

- [Novartis (Switzerland)](https://scholariq.org/institutions/novartis-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.